Raphael Pharmaceutical (RAPH) EBIT Growth (1y) (2021 - 2024)
Raphael Pharmaceutical (RAPH) EBIT Growth (1y) (2021 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | -150.77% |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | -10.00% |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | -0.93% |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | -9.25% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -97.30% |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 4.05% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 12.73% |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Raphael Pharmaceutical | 28.25 Mn | 28.25 Mn | - | 36.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -394.03% |
| Sep 30, 2024 | 56.24% |
| Jun 30, 2024 | 40.57% |
| Mar 31, 2024 | -112.02% |
| Dec 31, 2023 | 112.14% |
| Sep 30, 2023 | 48.88% |
| Jun 30, 2023 | 31.54% |
| Mar 31, 2023 | -47.43% |
| Dec 31, 2022 | -92.33% |
| Sep 30, 2022 | -241.15% |
| Jun 30, 2022 | -58.96% |
| Mar 31, 2022 | 30.56% |
| Dec 31, 2021 | -152.86% |